Constellation Pharmaceuticals (NASDAQ:CNST) issued its earnings results on Thursday. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.14), Fidelity Earnings reports.
CNST traded down $0.23 on Friday, reaching $5.86. The company had a trading volume of 6,229 shares, compared to its average volume of 19,381. Constellation Pharmaceuticals has a fifty-two week low of $5.57 and a fifty-two week high of $12.21.
A number of brokerages have recently issued reports on CNST. JPMorgan Chase & Co. began coverage on shares of Constellation Pharmaceuticals in a report on Monday, August 13th. They issued an “overweight” rating and a $17.00 target price on the stock. BMO Capital Markets began coverage on shares of Constellation Pharmaceuticals in a report on Monday, August 13th. They issued an “outperform” rating and a $19.00 target price on the stock. Oppenheimer set a $21.00 target price on shares of Constellation Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, November 1st. Zacks Investment Research cut shares of Constellation Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 23rd. Finally, Cann began coverage on shares of Constellation Pharmaceuticals in a report on Monday, August 13th. They issued an “outperform” rating and a $21.00 target price on the stock. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $17.15.
COPYRIGHT VIOLATION WARNING: This news story was first published by BBNS and is owned by of BBNS. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://baseballnewssource.com/2018/11/10/constellation-pharmaceuticals-cnst-releases-earnings-results-misses-expectations-by-0-14-eps/2973218.html.
Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidate CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors, as well as for the treatment of solid tumors in combination with immune checkpoint inhibitors.
See Also: Trading Strategy Examples and Plans
Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.